Promising results reported from two-year Tysabri study

04/13/2005 | Reuters

A two-year study of the multiple sclerosis drug Tysabri, withdrawn from the market in February because it was linked to adverse reactions, showed promising results in treating MS, Biogen Idec and Elan reported yesterday. Treatment with Tysabri significantly reduced the progression of disability, the rate of relapses and brain lesions, the companies said, adding they are working with regulators "to define the appropriate benefit-risk profile" for the drug.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC